Results 121 to 130 of about 19,292 (214)

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek   +16 more
wiley   +1 more source

Tumor Necrosis Factor Alpha (TNFα) Gene Promoter Polymorphisms and Haplotypes are Associated with the Febrile Seizure (FS) and TNFα Serum Levels. [PDF]

open access: yesIran J Child Neurol, 2023
Ghanbarzadeh B   +7 more
europepmc   +1 more source

Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta‐analysis

open access: yesBritish Journal of Haematology, EarlyView.
Summary Anti‐cluster of differentiation 38 (Anti‐CD38) monoclonal antibodies such as daratumumab are widely used in multiple myeloma (MM), yet the timing and magnitude of infectious risk remain incompletely defined. We performed an individual patient‐level meta‐analysis of six randomized trials (N = 2989) comparing daratumumab‐ versus non‐daratumumab ...
Alissa Visram   +7 more
wiley   +1 more source

Can epilepsy be predicted after the first febrile seizure? Insights from machine learning of postictal EEG. [PDF]

open access: yesEpileptic Disord
Şekeroğlu B   +7 more
europepmc   +1 more source

Evaluation of Febrile Seizure Diagnoses Associated With COVID-19. [PDF]

open access: yesJ Child Neurol, 2022
Cadet K   +4 more
europepmc   +1 more source

Beyond the seizure: the role of post-event observation in febrile seizure management. [PDF]

open access: yesEur J Pediatr
Test G   +9 more
europepmc   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

open access: yesBritish Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy